What is Noble Financial’s Forecast for GYRE Q2 Earnings?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Investment analysts at Noble Financial issued their Q2 2026 EPS estimates for shares of Gyre Therapeutics in a report issued on Friday, May 8th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for Gyre Therapeutics’ current full-year earnings is ($0.30) per share. Noble Financial also issued estimates for Gyre Therapeutics’ Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.16) EPS.

Other analysts have also issued research reports about the company. Wall Street Zen lowered Gyre Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday. Finally, Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Up 3.0%

Shares of GYRE stock opened at $7.30 on Wednesday. Gyre Therapeutics has a 12 month low of $6.57 and a 12 month high of $11.78. The company’s fifty day simple moving average is $7.51 and its 200-day simple moving average is $7.67. The firm has a market cap of $708.32 million, a PE ratio of -81.10 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The firm had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.

Insider Buying and Selling at Gyre Therapeutics

In other news, CEO Ying Luo sold 10,136 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total transaction of $81,493.44. Following the transaction, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at $20,624,417.04. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.00% of the stock is owned by corporate insiders.

Institutional Trading of Gyre Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after purchasing an additional 14,365 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Gyre Therapeutics by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock worth $301,000 after buying an additional 1,941 shares in the last quarter. Barclays PLC boosted its stake in shares of Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after buying an additional 5,135 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after acquiring an additional 45,772 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.